カテゴリ： GlobalData, アメリカ, 企業調査

AMAG Pharmaceuticals Inc (AMAG)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：AMAG Pharmaceuticals Inc (AMAG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012243
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in women, Feraheme (ferumoxytol) for iron deficiency anemia in adult patients with chronic kidney disease and MuGard Oral Mucoadhesive for the management of oral mucositis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers these products through direct sales and a network of distributors. It has presence in the US, Switzerland and the UK. AMAG is headquartered in Waltham, Massachusetts, the US.

AMAG Pharmaceuticals Inc (AMAG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
AMAG Pharma Enters into Option Agreement to Acquire Rights of Orphan Drug Candidate from Velo Bio 14
Private Equity 15
GTCR Invests In Cord Blood Registry 15
MSMB Capital Management To Acquire AMAG Pharma 16
Partnerships 17
Cord Blood Registry Enters into Research Agreement with Cellular Dynamics 17
Licensing Agreements 18
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 18
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 22
Equity Offering 24
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 24
AMAG Pharma Raises USD201 Million in Public Offering of Shares 26
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 28
Debt Offering 29
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 29
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 31
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 32
Asset Transactions 34
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 34
Acquisition 35
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 35
AMAG Pharma Acquires Lumara Health 37
AMAG Pharma Plans For Sale Of The Company 39
AMAG Pharmaceuticals Inc – Key Competitors 40
AMAG Pharmaceuticals Inc – Key Employees 41
AMAG Pharmaceuticals Inc – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 45
Financial Announcements 45
Nov 02, 2017: AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights 45
Aug 03, 2017: AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 48
May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 52
Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 54
Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 57
Nov 03, 2016: AMAG Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 59
Aug 09, 2016: AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 61
May 03, 2016: AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results 64
Feb 17, 2016: AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 66
Corporate Communications 68
Sep 29, 2017: AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer 68
Sep 07, 2017: AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development 69
Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 70
Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 71
Dec 21, 2016: AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors 72
Apr 11, 2016: AMAG Pharmaceuticals Appoints Edward Myles as Chief Financial Officer 73
Jan 04, 2016: AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer 74
Government and Public Interest 75
Dec 15, 2016: AMAG Pharmaceuticals Doubles Support of Prematurity Prevention Research 75
Product News 76
04/04/2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 76
02/02/2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration 77
Product Approvals 78
Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector 78
Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use 79
Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 81
Clinical Trials 82
Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena 82
Other Significant Developments 83
Nov 08, 2017: AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy 83
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMAG Pharma Enters into Option Agreement to Acquire Rights of Orphan Drug Candidate from Velo Bio 14
GTCR Invests In Cord Blood Registry 15
MSMB Capital Management To Acquire AMAG Pharma 16
Cord Blood Registry Enters into Research Agreement with Cellular Dynamics 17
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 18
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 22
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 24
AMAG Pharma Raises USD201 Million in Public Offering of Shares 26
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 28
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 29
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 31
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 32
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 34
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 35
AMAG Pharma Acquires Lumara Health 37
AMAG Pharma Plans For Sale Of The Company 39
AMAG Pharmaceuticals Inc, Key Competitors 40
AMAG Pharmaceuticals Inc, Key Employees 41
AMAG Pharmaceuticals Inc, Other Locations 43
AMAG Pharmaceuticals Inc, Subsidiaries 43

★海外企業調査レポート[AMAG Pharmaceuticals Inc (AMAG)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • ITOCHU Corporation：企業の戦略・SWOT・財務情報
    ITOCHU Corporation - Strategy, SWOT and Corporate Finance Report Summary ITOCHU Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Bioverativ Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technolog …
  • Terumo BCT Inc：企業の戦略的SWOT分析
    Terumo BCT Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • TenneT Holding BV：電力：M&Aディール及び事業提携情報
    Summary TenneT Holding BV (TenneT), owned by the Ministry of Finance of The State of the Netherlands, is an electricity transmission system operator. The company offers electricity transmission and system services. It constructs and maintains high voltage grid to transmit electricity from the produc …
  • Dentsply Sirona Inc (XRAY)：医療機器：M&Aディール及び事業提携情報
    Summary Dentsply Sirona Inc (Dentsply Sirona) formerly Dentsply International Inc, is a medical device company that designs, develops, manufactures and markets a wide range of products for the dental market. It provides dental prosthetics, precious metal dental alloys, dental ceramics, endodontic in …
  • Xintela AB (XINT)：企業の財務・戦略的SWOT分析
    Summary Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company’s technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also p …
  • Actelion Ltd：企業の戦略・SWOT・財務情報
    Actelion Ltd - Strategy, SWOT and Corporate Finance Report Summary Actelion Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dukat dd (LURA-R-A)：企業の財務・戦略的SWOT分析
    Dukat dd (LURA-R-A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Da Afghanistan Breshna Sherkat：企業の戦略的SWOT分析
    Da Afghanistan Breshna Sherkat - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Snyder’s-Lance, Inc.：戦略・SWOT・企業財務分析
    Snyder's-Lance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Snyder's-Lance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • S Chand And Company Limited (SCHAND)：企業の財務・戦略的SWOT分析
    S Chand And Company Limited (SCHAND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • ONEOK Partners LP：企業の戦略的SWOT分析
    ONEOK Partners LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Merus NV (MRUS)：製薬・医療：M&Aディール及び事業提携情報
    Summary Merus NV (Merus) is a clinical-stage immuno-oncology company that discovers and develops human bispecific antibody therapeutics for the treatment of cancer. The company’s pipeline antibody candidates are intended for the treatment of breast cancer, ovarian cancer, colorectal cancer, acute my …
  • Schindler Holding Ltd.：企業の戦略・SWOT・財務情報
    Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report Summary Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • IntraPace Inc-医療機器分野：企業M&A・提携分析
    Summary IntraPace Inc (IntraPace) is a medical device company that develops novel implantable systems. The company provides abiliti systems that contains sensors intended to track consumption events and physical activity using this information to direct when therapy is delivered and to monitor a pat …
  • Standard Chartered Private Bank：企業の戦略・SWOT・財務情報
    Standard Chartered Private Bank - Strategy, SWOT and Corporate Finance Report Summary Standard Chartered Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • DIC Corp (4631)：企業の財務・戦略的SWOT分析
    DIC Corp (4631) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Aspial Corporation Ltd (A30)：企業の財務・戦略的SWOT分析
    Aspial Corporation Ltd (A30) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Taragenyx Ltd：製品パイプライン分析
    Summary Taragenyx Ltd (Taragenyx) is a medical technology company that offers regenerative medicine technology, medical and biological engineering solutions. The company provides restorative implant solutions generation, burdensome operations, and medical, orthopedic and dental implantation solution …
  • Nexus AG (NXU)：企業の財務・戦略的SWOT分析
    Summary Nexus AG (Nexus) is a healthcare technology company that provides healthcare software solutions. The company provides products such as NEXUS and HIS, a hospital information system; NEXUS and DIS, a special ward and department solutions; and NEXUS and QM, a solution in quality management, amo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆